Troutman Sanders Adds More IP Attorneys

NEW YORK – June 25, 2012 – For the second time in recent weeks, the law firm of Troutman Sanders LLP has added a high-profile Intellectual Property team to its New York office.

Joining Troutman Sanders are partner Louis J. DelJuidice, of counsel Hiroyuki Yasuda and patent agent Nicole R. Sullivan, Ph.D. All three were previously at McDermott Will & Emery LLP, as was a group of four attorneys who arrived at Troutman Sanders in May 2012.

“The addition of Lou DelJuidice and his Intellectual Property team marks another significant boost to our New York office and the firm’s nationwide IP practice,” said Aurora Cassirer, managing partner of the New York office. “In the span of just over a month, we have added six outstanding IP attorneys here.”

DelJuidice focuses his practice on litigation, prosecution and client counseling in the electromechanical, cellular telephone, computer and medical device areas. He specializes in preparing and prosecuting both inter partes and ex parte reexaminations as both requestor and owner as well as legal opinions on issues relating to patentability, freedom to operate, noninfringement and invalidity.

An important portion of DelJuidice’s practice involves managing portfolios for U.S. and Japanese clients, as well as auditing and performing due diligence on intellectual property assets in the furtherance of licensing.

“Troutman Sanders provides a great platform to service my clients in Asia, particularly in Japan, and is committed to the region,” DelJuidice said.

He has represented clients in a wide range of technologies including DVD, audio equipment, cellular telephone, digital rights management (DRM), digital watermarking, internet content providers, optics for digital cameras, cutting tools, dialysis machines, absorbent articles, semiconductors, printed circuit board and circuit board connector technologies.

DelJuidice has been active in numerous litigation matters. His experience includes noninfringement and invalidity defenses, claim construction, discovery, analyzing potential patent infringers and pre-filing due diligence fact finding. The Legal 500 United States has ranked Louis as one of the leading patent litigation lawyers in the United States.

Yasuda, who is fluent in Japanese, focuses his practice on patent litigation and prosecution, particularly in the areas of mechanical, electromechanical and medical device technologies. He has worked on patent infringement litigations before district courts such as the U.S. District Courts for the Eastern District of Texas and the Northern District of Illinois, involving technologies relating to motor vehicles and medical devices. Further, he has provided legal opinions and pre-litigation advice to clients on issues relating to patent infringement, validity and freedom to operate, in a broad range of technologies.

He has also prepared and prosecuted numerous patent applications, and conducted appellate and ex parte/inter partes reexamination work, in a broad range of technologies including medical devices, mobile communications, copiers, DVD devices, printed wiring boards, semiconductor fabricating apparatuses and consumer electrical products.

Prior to joining Troutman Sanders, Yasuda was an intellectual property attorney at prominent law firms in New York and Washington, D.C. He has also been active in organizing lectures and seminars for Japanese clients and the Japanese legal community in the metropolitan New York area.

Sullivan focuses her work on U.S. and foreign patent prosecution in the biotechnology, pharmaceutical, bioengineering and molecular biology fields. She assists with patent due diligence, opinion letters, patentability assessments, inter partes reexaminations and patent litigation.

Prior to becoming a patent agent, Sullivan was a scientific advisor at an international patent law firm and a senior research scientist at Wyeth Pharmaceuticals, where she worked in research and development in the Department of Pain’s Molecular Pharmacology Group. In this position, she served as a program leader for two drug discovery targets.